The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity: The role of autophagy

Rita Zilinyi, Attila Czompa, Andras Czegledi, Andrea Gajtko, Dora Pituk, I. Lekli, A. Tósaki

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The molecular mechanisms underlying doxorubicin-induced cardiotoxicity are still being investigated, but are known to involve oxidative stress, mitochondrial dysfunction, and the dysregulation of autophagy. The objective of the current study was to examine the protective role of metformin and its effect on autophagy in doxorubicin-induced cardiotoxicity. Sprague–Dawley rats were divided into four groups at random. The doxorubicin-treated group received doxorubicin (3 mg/kg every second day) intraperitoneally. The metformin-treated group received 250 mg/kg/day metformin via gavage. The doxorubicin + metformin-treated group received both at the above-mentioned doses. The control group received vehicle only. Following the two-week treatment, the hearts were isolated, and cardiac functions were registered. Serum levels of lactate dehydrogenase (LDH), creatine kinase iso-enzyme MB (CK-MB) enzyme, Troponin T, and cardiac malondialdehyde (MDA) were also measured. Heart tissue samples were histopathologically examined by using Masson’s trichrome staining and Western blot analysis was conducted for evaluating the expression level of AMP-activated protein kinase (AMPK) and autophagy-associated proteins beclin-1, LC3B-II, and p62, respectively. The results revealed that treatment with metformin conferred increased cardiac protection against the development of cardiotoxicity manifested by a significant decrease in serum Troponin T and cardiac MDA levels, and remarkable improvement in heart function in connection with histopathological features. Furthermore, by focusing on the contribution of autophagic proteins, it was found that metformin normalised autophagy, which may help cardiomyocytes survive doxorubicin-induced toxicity. These results promote the use of metformin, which would be a preferable drug for patients receiving doxorubicin.

Original languageEnglish
Article number1184
JournalMolecules
Volume23
Issue number5
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Metformin
Autophagy
Doxorubicin
proteins
serums
Troponin T
enzymes
heart function
creatine
Malondialdehyde
adenosine monophosphate
lactates
dehydrogenases
staining
toxicity
rats
AMP-Activated Protein Kinases
Oxidative stress
vehicles
drugs

Keywords

  • AMPK
  • Autophagy
  • Cardiotoxicity
  • Doxorubicin
  • Heart failure
  • Metformin

ASJC Scopus subject areas

  • Analytical Chemistry
  • Chemistry (miscellaneous)
  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Organic Chemistry

Cite this

The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity : The role of autophagy. / Zilinyi, Rita; Czompa, Attila; Czegledi, Andras; Gajtko, Andrea; Pituk, Dora; Lekli, I.; Tósaki, A.

In: Molecules, Vol. 23, No. 5, 1184, 01.01.2018.

Research output: Contribution to journalArticle

Zilinyi, Rita ; Czompa, Attila ; Czegledi, Andras ; Gajtko, Andrea ; Pituk, Dora ; Lekli, I. ; Tósaki, A. / The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity : The role of autophagy. In: Molecules. 2018 ; Vol. 23, No. 5.
@article{761e287dc1ac472da0e536cc40edae4c,
title = "The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity: The role of autophagy",
abstract = "The molecular mechanisms underlying doxorubicin-induced cardiotoxicity are still being investigated, but are known to involve oxidative stress, mitochondrial dysfunction, and the dysregulation of autophagy. The objective of the current study was to examine the protective role of metformin and its effect on autophagy in doxorubicin-induced cardiotoxicity. Sprague–Dawley rats were divided into four groups at random. The doxorubicin-treated group received doxorubicin (3 mg/kg every second day) intraperitoneally. The metformin-treated group received 250 mg/kg/day metformin via gavage. The doxorubicin + metformin-treated group received both at the above-mentioned doses. The control group received vehicle only. Following the two-week treatment, the hearts were isolated, and cardiac functions were registered. Serum levels of lactate dehydrogenase (LDH), creatine kinase iso-enzyme MB (CK-MB) enzyme, Troponin T, and cardiac malondialdehyde (MDA) were also measured. Heart tissue samples were histopathologically examined by using Masson’s trichrome staining and Western blot analysis was conducted for evaluating the expression level of AMP-activated protein kinase (AMPK) and autophagy-associated proteins beclin-1, LC3B-II, and p62, respectively. The results revealed that treatment with metformin conferred increased cardiac protection against the development of cardiotoxicity manifested by a significant decrease in serum Troponin T and cardiac MDA levels, and remarkable improvement in heart function in connection with histopathological features. Furthermore, by focusing on the contribution of autophagic proteins, it was found that metformin normalised autophagy, which may help cardiomyocytes survive doxorubicin-induced toxicity. These results promote the use of metformin, which would be a preferable drug for patients receiving doxorubicin.",
keywords = "AMPK, Autophagy, Cardiotoxicity, Doxorubicin, Heart failure, Metformin",
author = "Rita Zilinyi and Attila Czompa and Andras Czegledi and Andrea Gajtko and Dora Pituk and I. Lekli and A. T{\'o}saki",
year = "2018",
month = "1",
day = "1",
doi = "10.3390/molecules23051184",
language = "English",
volume = "23",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity

T2 - The role of autophagy

AU - Zilinyi, Rita

AU - Czompa, Attila

AU - Czegledi, Andras

AU - Gajtko, Andrea

AU - Pituk, Dora

AU - Lekli, I.

AU - Tósaki, A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The molecular mechanisms underlying doxorubicin-induced cardiotoxicity are still being investigated, but are known to involve oxidative stress, mitochondrial dysfunction, and the dysregulation of autophagy. The objective of the current study was to examine the protective role of metformin and its effect on autophagy in doxorubicin-induced cardiotoxicity. Sprague–Dawley rats were divided into four groups at random. The doxorubicin-treated group received doxorubicin (3 mg/kg every second day) intraperitoneally. The metformin-treated group received 250 mg/kg/day metformin via gavage. The doxorubicin + metformin-treated group received both at the above-mentioned doses. The control group received vehicle only. Following the two-week treatment, the hearts were isolated, and cardiac functions were registered. Serum levels of lactate dehydrogenase (LDH), creatine kinase iso-enzyme MB (CK-MB) enzyme, Troponin T, and cardiac malondialdehyde (MDA) were also measured. Heart tissue samples were histopathologically examined by using Masson’s trichrome staining and Western blot analysis was conducted for evaluating the expression level of AMP-activated protein kinase (AMPK) and autophagy-associated proteins beclin-1, LC3B-II, and p62, respectively. The results revealed that treatment with metformin conferred increased cardiac protection against the development of cardiotoxicity manifested by a significant decrease in serum Troponin T and cardiac MDA levels, and remarkable improvement in heart function in connection with histopathological features. Furthermore, by focusing on the contribution of autophagic proteins, it was found that metformin normalised autophagy, which may help cardiomyocytes survive doxorubicin-induced toxicity. These results promote the use of metformin, which would be a preferable drug for patients receiving doxorubicin.

AB - The molecular mechanisms underlying doxorubicin-induced cardiotoxicity are still being investigated, but are known to involve oxidative stress, mitochondrial dysfunction, and the dysregulation of autophagy. The objective of the current study was to examine the protective role of metformin and its effect on autophagy in doxorubicin-induced cardiotoxicity. Sprague–Dawley rats were divided into four groups at random. The doxorubicin-treated group received doxorubicin (3 mg/kg every second day) intraperitoneally. The metformin-treated group received 250 mg/kg/day metformin via gavage. The doxorubicin + metformin-treated group received both at the above-mentioned doses. The control group received vehicle only. Following the two-week treatment, the hearts were isolated, and cardiac functions were registered. Serum levels of lactate dehydrogenase (LDH), creatine kinase iso-enzyme MB (CK-MB) enzyme, Troponin T, and cardiac malondialdehyde (MDA) were also measured. Heart tissue samples were histopathologically examined by using Masson’s trichrome staining and Western blot analysis was conducted for evaluating the expression level of AMP-activated protein kinase (AMPK) and autophagy-associated proteins beclin-1, LC3B-II, and p62, respectively. The results revealed that treatment with metformin conferred increased cardiac protection against the development of cardiotoxicity manifested by a significant decrease in serum Troponin T and cardiac MDA levels, and remarkable improvement in heart function in connection with histopathological features. Furthermore, by focusing on the contribution of autophagic proteins, it was found that metformin normalised autophagy, which may help cardiomyocytes survive doxorubicin-induced toxicity. These results promote the use of metformin, which would be a preferable drug for patients receiving doxorubicin.

KW - AMPK

KW - Autophagy

KW - Cardiotoxicity

KW - Doxorubicin

KW - Heart failure

KW - Metformin

UR - http://www.scopus.com/inward/record.url?scp=85047178739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047178739&partnerID=8YFLogxK

U2 - 10.3390/molecules23051184

DO - 10.3390/molecules23051184

M3 - Article

C2 - 29762537

AN - SCOPUS:85047178739

VL - 23

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 5

M1 - 1184

ER -